Sign Up to like & get
recommendations!
1
Published in 2021 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-21-0175
Abstract: Activating mutations in RAS are found in approximately 30% of human cancers, resulting in the delivery of a persistent signal to critical downstream effectors that drive tumorigenesis. RAS-driven malignancies respond poorly to conventional cancer treatments…
read more here.
Keywords:
screening platform;
platform identify;
development;
ras raf ... See more keywords